Paradojas...: Bifosfonatos (Actonel, Boniva, Fosamax, Reclast) y fractura de cadera

A popular group of drugs prescribed to slow bone loss may be putting some patients at an increased risk of hip fractures if taken for more than five years.

Two new studies show the bones of some post-menopausal women who take bisphosphonates (Actonel, Boniva, Fosamax, Reclast) to ward off osteoporosis can stop rejuvenating and become brittle after long-term use.

"That's the paradox," says Melvin Rosenwasser, chief of orthopedic trauma surgery at Columbia University Medical Center in New York. "These drugs are good drugs. They strengthen bone and protect you from fractures for a while. But in some people they can become deleterious after a period of time."

The Food and Drug Administration is reviewing the issue of long-term bisphosphonate use but has not seen the new studies, says spokesman Elaine Bobo. (Ver)

Ver:

BIFOSFONATOS: Medicos y dentistas, en pugna por el risgo de un fármaco